Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [4]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-79035 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Factor D Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 µg/mL.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 500 µg/mL
- Storage
- -20°C
Submitted references Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19.
Niederreiter J, Eck C, Ries T, Hartmann A, Märkl B, Büttner-Herold M, Amann K, Daniel C
Frontiers in immunology 2022;13:835156
Frontiers in immunology 2022;13:835156
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Factor D on paraffin-embedded rat lung tissue. Antigen retrieval was performed using citrate buffer (pH6, epitope retrieval solution) for 20 mins. Sample was blocked using 10% goat serum, incubated with Factor D polyclonal antibody (Product# PA5-79035) with a dilution of 1 µg/mL (overnight at 4°C), and followed by biotinylated goat anti-rabbit IgG (30 minutes at 37°C). Development was performed using Streptavidin-Biotin-Complex (SABC) with DAB chromogen method.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Factor D on paraffin-embedded rat small intestine tissue. Antigen retrieval was performed using citrate buffer (pH6, epitope retrieval solution) for 20 mins. Sample was blocked using 10% goat serum, incubated with Factor D polyclonal antibody (Product# PA5-79035) with a dilution of 1 µg/mL (overnight at 4°C), and followed by biotinylated goat anti-rabbit IgG (30 minutes at 37°C). Development was performed using Streptavidin-Biotin-Complex (SABC) with DAB chromogen method.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Factor D on paraffin-embedded mouse lung tissue. Antigen retrieval was performed using citrate buffer (pH6, epitope retrieval solution) for 20 mins. Sample was blocked using 10% goat serum, incubated with Factor D polyclonal antibody (Product# PA5-79035) with a dilution of 1 µg/mL (overnight at 4°C), and followed by biotinylated goat anti-rabbit IgG (30 minutes at 37°C). Development was performed using Streptavidin-Biotin-Complex (SABC) with DAB chromogen method.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Factor D on paraffin-embedded rat small intestine tissue. Antigen retrieval was performed using citrate buffer (pH6, epitope retrieval solution) for 20 mins. Sample was blocked using 10% goat serum, incubated with Factor D polyclonal antibody (Product# PA5-79035) with a dilution of 1 µg/mL (overnight at 4°C), and followed by biotinylated goat anti-rabbit IgG (30 minutes at 37°C). Development was performed using Streptavidin-Biotin-Complex (SABC) with DAB chromogen method.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Detection of the alternative pathway component CFD in lung and kidney samples from patients with COVID-19. Overview of immunohistochemical staining for complement factor D (CFD) in lung samples of a control patient (A) and a patient with COVID-19 (B) was shown. Results of semi-quantitative scoring in multiple compartments for CFD deposition in the lung were summarized in a sum score (C) and overview of the mean values of compartment-specific analyses is given in a heat map (D) . Representative CFD stainings in alveolar septa of a control patient (E) and a COVID-19 patient (F) and comparative analyses are shown (G) . CFD staining in alveolar lumina in a control patient (H) and a patient with COVID-19 (I) and statistical comparison of both groups (J) . Overview of CFD staining in kidney samples of a control patient (K) and a patient with COVID-19 (L) . Results of semi-quantitative scoring in multiple compartments for CFD deposition in the kidney are summarized in a sum score (M) and overview of the mean values of compartment-specific analyses is given in a heat map (N) . Representative CFD staining in peritubular capillaries of a control patient (O) and a COVID-19 patient ( P , arrows) and a comparative analyses (Q) . CFD staining of tubular basement membrane in a control patient (R) and a patient with COVID-19 ( S , arrows) and comparison of both groups (T) . AS, alveolar septa; A inf, accumulation of alveolar inflammatory cells; A lumen, alveolar lumen; Bro, bronchioles; Vasc
